Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
260,50 € ↑8,70 (3,46%)
2026-06-04
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionAndra AP-fonden
Latest Disclosed Ownership86,697 shares
Latest Disclosed Value $ 28,685,436
Andra AP-fonden reports 78.61% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 8, 2026 - Andra AP-fonden filed a 13F-HR form disclosing ownership of 86,697 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $24,769,333 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 48,540 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 78.61% during the quarter. The current value of the position is $22,584,568 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 86,697 38,157 78.61 28,685 48.62 0.3418
2026-02-12 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,540 27,840 134.49 19,302 104.48 0.2385
2025-11-12 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 20,700 13,800 200.00 9,439 319.51 0.1206
2025-08-06 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 6,900 -9,900 -58.93 2,250 -50.40 0.0313
2025-05-13 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,800 -11,100 -39.78 4,536 -30.91 0.0744
2025-02-07 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 27,900 15,200 119.69 6,565 88.00 0.1052
2024-11-12 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,700 9,600 309.68 3,493 363.75 0.0514
2024-08-07 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 3,100 3,100 753 0.0127
2024-05-13 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -35,500 -100.00 0 -100.00
2024-02-15 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 35,500 1,000 2.90 6,795 11.23 0.3598
2023-11-09 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 34,500 -6,000 -14.81 6,110 -20.58 0.3602
2023-08-09 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 40,500 -4,700 -10.40 7,693 -15.04 0.1946
2023-05-12 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,200 -10,400 -18.71 9,054 69,546.15 0.2355
2023-02-13 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 55,600 7,000 14.40 13 -99.87 0.4005
2022-11-14 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,600 6,500 15.44 9,728 58.44 0.3187
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 42,100 13,700 48.24 6,140 27.49 0.1758
2022-02-15 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 28,400 8,500 42.71 4,816 28.19 0.0981
2021-11-12 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 19,900 2,500 14.37 3,757 27.36 0.0773
2021-08-16 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 17,400 1,400 8.75 2,950 30.59 0.0602
2021-05-17 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 16,000 -2,500 -13.51 2,259 -6.03 0.0498
2021-02-12 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 18,500 4,300 30.28 2,404 16.25 0.0530
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,200 -23,900 -62.73 2,068 -63.35 0.0561
2020-08-06 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 38,100 3,700 10.76 5,643 50.72 0.1642
2020-05-13 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 34,400 20,000 138.89 3,744 125.81 0.1361
2020-02-10 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,400 11,600 414.29 1,658 636.89 0.0474
2019-11-19 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,800 2,800 225 0.0067
2019-08-15 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -5,600 -100.00 0 -100.00
2019-05-14 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 5,600 5,600 523 0.0152
2018-10-16 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -12,800 -100.00 0 -100.00
2018-08-17 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 12,800 -1,900 -12.93 1,261 -27.98 0.0341
2018-04-10 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 14,700 12,800 673.68 1,751 626.56 0.0454
2018-02-14 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,900 1,900 241 0.0055
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.